Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs

Oncogene

Volumn 32, Issue 20, 2013, Pages 2527-2533

  Garcia, A Galan ^a   Nedev, H ^a   Bijian, K ^a   Su, J ^a   Alaoui Jamali, M A ^a,b,c   Saragovi, H U ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Conjugate; Herceptin; Metastasis; Therapeutic window

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; PACLITAXEL; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84878016500     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.283     Document Type: Article

References (46)

1. Monneret C. Recent developments in the field of antitumour anthracyclines. Eur J Med Chem 2001; 36: 483-493. (Pubitemid 32781712)
2. Menzin AW, King SA, Aikins JK, Mikuta JJ, Rubin SC. Taxol (paclitaxel) was approved by FDA for the treatment of patients with recurrent ovarian cancer. Gynecol Oncol 1994; 54: 103.
3. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 9182-9187. (Pubitemid 14098903)
4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-667. (Pubitemid 9114288)
5. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-1565. (Pubitemid 10073801)
6. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-1047.
7. da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol 2001; 1: 364-369. (Pubitemid 33585985)
8. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M. Pharmacokinetic- pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41: 431-444. (Pubitemid 34753680)
9. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999; 12: 565-571. (Pubitemid 30028616)
10. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-1157. (Pubitemid 41486396)
11. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302. (Pubitemid 38541581)
12. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9: 423-430.
13. Barros FF, Powe DG, Ellis IO, Green AR. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 2010; 56: 560-572.
14. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146: 264-275.
15. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008; 44: 2806-2812.
16. Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2- targeted therapies. Exp Mol Pathol 2009; 87: 1-11.
17. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-280. (Pubitemid 43731112)
18. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009; 15: 7479-7491.
19. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 2008; 19: 2321-2331.
20. Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol 2005; 24: 350-358. (Pubitemid 40840343)
21. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 2004; 4: 313-326. (Pubitemid 38797243)
22. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptornegative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370. (Pubitemid 28439960)
23. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15. J Natl Cancer Inst 2000; 92: 1991-1998. (Pubitemid 32045895)
24. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-2111. (Pubitemid 43736610)
25. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.
26. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracyclinetrastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008; 19: 1530-1539.
27. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
28. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumabmediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001; 28: 12-17. (Pubitemid 33065105)
29. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti- HER-2 therapies: what have we learned so far? Target Oncol 2009; 4: 77-88.
30. Guillemard V, Saragovi HU. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res 2001; 61: 694-699. (Pubitemid 32140477)
31. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14: 529-537.
32. Guillemard V, Saragovi HU. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 2004; 23: 3613-3621. (Pubitemid 38658428)
33. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290.
34. Kojic LD, Wiseman SM, Ghaidi F, Joshi B, Nedev H, Saragovi HU et al. Raftdependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells. PloS One 2008; 3: e3597.
35. Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M et al. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 2005; 171: 505-516. (Pubitemid 41586939)
36. Stockmeyer B, Beyer T, Neuhuber W, Repp R, Kalden JR, Valerius T et al. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 2003; 171: 5124-5129. (Pubitemid 37432795)
37. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999; 27: 1533-1541. (Pubitemid 29458428)
38. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 2009; 15: 1973-1980.
39. Nabholtz JM, Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 2005; 6: 1073-1094. (Pubitemid 40959472)
40. Tubiana-Hulin M. How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev 2005; 31: S3-S9. (Pubitemid 41782956)
41. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 2698-2704.
42. Kato H, Faria TN, Stannard B, Roberts Jr CT, LeRoith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 1993; 268: 2655-2661. (Pubitemid 23057892)
43. Yen L, Benlimame N, Nie ZR, Xiao D, Wang T, Al Moustafa AE et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 2002; 13: 4029-4044. (Pubitemid 35398568)
44. Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA. Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells. Br J Cancer 2009; 100: 633-643.
45. Omelyanenko V, Kopeckova P, Gentry C, Shiah JG, Kopecek J. HPMA copolymeranticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target 1996; 3: 357-373. (Pubitemid 26059826)
46. Stan AC, Radu DL, Casares S, Bona CA, Brumeanu TD. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res 1999; 59: 115-121. (Pubitemid 29062966)